Gary D. HammerGary Hammer, MD, PhD serves as Director of the Endocrine Oncology Program in the Rogel Cancer Center at the University of Michigan where he holds the Millie Schembechler Professorship in Adrenal Cancer. The Program is recognized as a worldwide leaderin endocrine cancers - exemplified by its recent leadership role in the 3 recent endocrine cancer platforms of the NCI TCGA (papillary thyroid cancer, adrenocortical carcinoma and pheochromocytoma). A worldwide leader in the adrenal community, Dr. Hammer is best recognized for his research in adrenal homeostasis and neoplasia and for the treatment of adrenal cancer. Most recently, Dr. Hammer cofounded Millendo Inc., a biotechnology company focusing on therapies for adrenal cancer and other related endocrine diseases of steroid excess. Dr. Hammer has been the PI or Co-Investigator on several NIH and institutional funded grants. Read More Read Less